Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743791 · ClinicalTrials.gov registry record · Phase 4
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
A Phase 4 study of Asthma, sponsored by Sally E. Wenzel MD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04743791: Recruiting Phase 4 study of Asthma, sponsored by Sally E. Wenzel MD.
NCT04743791 is a Phase 4 study of Asthma that is actively recruiting participants, run by Sally E. Wenzel MD. The registered enrollment target is 30 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04743791, a Phase 4 study of Asthma, is actively recruiting participants, sponsored by Sally E. Wenzel MD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Primary Outcome
MCC is measured using an aerosol-based nuclear imaging technique
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
Study Locations (1)
Pennsylvania
- The University of Pittsburgh Asthma Institute at UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT04743791 shows while recruiting
NCT04743791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04743791 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04743791 about?
NCT04743791 is a clinical study titled "Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma". Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
What is the current status of trial NCT04743791?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2022-10-17. Estimated completion is 2026-09.
What conditions does trial NCT04743791 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT04743791?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT04743791?
This trial is sponsored by Sally E. Wenzel MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743791 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04743791's enrollment target sits among peer trials
30 305th of 374 higher than 66 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI